NXC680 / Nextgen Biosci - LARVOL DELTA

HK inno.N said Monday it has signed a joint research and development agreement with Nextgen Bioscience for 'NXC680', a drug candidate for the treatment of idiopathic pulmonary fibrosis (IPF) (Korea Biomedical Review) - "Under the agreement, HK inno.N will be responsible for optimizing the finished drug formulation and managing clinical trials. Nextgen Bioscience will supply the active pharmaceutical ingredients and provide essential research data. Both companies plan to conduct phase 1 clinical trials jointly....It has already received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) and has obtained Investigational New Drug (IND) approval for phase 1 clinical trials in Korea."

Licensing / partnership • New P1 trial • Orphan drug • Idiopathic Pulmonary Fibrosis

Nextgen’s idiopathic pulmonary fibrosis treatment, designated as an orphan drug by the US FDA [Google translation] (docdocdoc.co.kr) - "Nextgen Bioscience...announced on the 26th that the U.S. Food and Drug Administration (FDA) has designated 'NXC680', a drug candidate for idiopathic pulmonary fibrosis (IPF), as an Orphan Drug Designation (ODD)....Nextgen plans to apply for an IND (clinical trial protocol) for domestic phase 1 clinical trial of NXC680 in the second quarter of this year, and is planning to accelerate discussions on business development from various angles for global technology transfer of NXC680."

IND • Orphan drug • Idiopathic Pulmonary Fibrosis • Interstitial Lung Disease